[Form 4] ImmunityBio, Inc. Insider Trading Activity

Rhea-AI Filing Summary

ImmunityBio, Inc.’s Chief Accounting Officer, Regan J. Lauer, reported RSU vesting and related share movements. On February 10, 2026, 5,482 restricted stock units were converted into 5,482 shares of common stock at an exercise price of $0, increasing directly held common shares to 115,740.

On the same date, 2,257 common shares were withheld at $6.93 per share to cover tax obligations tied to the vesting, leaving 113,483 common shares held directly after the withholding. Following these transactions, Lauer also directly held 10,965 restricted stock units, which vest over three years starting from a February 10, 2025 commencement date.

Insider Trade Summary

5,482 shares exercised/converted

Mixed 3 txns

Insider LAUER REGAN J

Role Chief Accounting Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	5,482	$0.00	--
Exercise	Common Stock	5,482	$0.00	--
Tax Withholding	Common Stock	2,257	$6.93	$16K

Holdings After Transaction: Restricted Stock Units — 10,965 shares (Direct); Common Stock — 115,740 shares (Direct)

Footnotes (1)

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock. On February 10, 2026, the reporting person's RSUs vested. The closing price of the Issuer's common stock on February 9, 2026 was the settlement price used to calculate the shares withheld. Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 10, 2025.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LAUER REGAN J

(Last) (First) (Middle)

C/O IMMUNITYBIO, INC.

3530 JOHN HOPKINS COURT

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ImmunityBio, Inc. [ IBRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	02/10/2026		M		5,482	A	$0	115,740	D
Common Stock	02/10/2026		F		2,257	D	$6.93(2)	113,483	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/10/2026		M			5,482	(3)	(3)	Common Stock	5,482	$0	10,965	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.

2. On February 10, 2026, the reporting person's RSUs vested. The closing price of the Issuer's common stock on February 9, 2026 was the settlement price used to calculate the shares withheld.

3. Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 10, 2025.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Philip LoScalzo, as Attorney-in-Fact	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did ImmunityBio (IBRX) report for Regan J. Lauer?

ImmunityBio’s Chief Accounting Officer, Regan J. Lauer, reported RSU vesting on February 10, 2026. 5,482 RSUs were converted into common shares, and 2,257 shares were withheld to cover tax obligations, reflecting routine equity compensation activity rather than an open-market trade.

How many ImmunityBio (IBRX) shares did Regan J. Lauer acquire through RSU vesting?

On February 10, 2026, Regan J. Lauer acquired 5,482 ImmunityBio common shares at an exercise price of $0 through the vesting of restricted stock units. These shares came from previously granted equity awards, not from a cash purchase in the open market.

Why were 2,257 ImmunityBio (IBRX) shares disposed of in this Form 4 filing?

The 2,257 ImmunityBio shares were withheld at $6.93 per share to satisfy tax liabilities arising from RSU vesting. This is a common administrative transaction, where shares are surrendered back to the issuer instead of paying taxes in cash.

How many ImmunityBio (IBRX) common shares does Regan J. Lauer hold after these transactions?

After the February 10, 2026 transactions, Regan J. Lauer directly held 113,483 ImmunityBio common shares. This figure reflects the net position following both the RSU conversion that increased holdings and the share withholding for taxes that reduced them.

What is the remaining RSU balance for Regan J. Lauer at ImmunityBio (IBRX)?

Following the reported vesting, Regan J. Lauer held 10,965 restricted stock units. Each RSU represents a contingent right to receive one ImmunityBio common share, subject to continued service and a three-year vesting schedule that began on February 10, 2025.

How do Regan J. Lauer’s RSUs at ImmunityBio (IBRX) vest over time?

Lauer’s RSUs vest over three years from a February 10, 2025 commencement date. 33.33% of the award vests on each of the first and second anniversaries, and 33.34% on the third anniversary, assuming continued service as defined in the company’s equity incentive plan.